Hydroxyurea Medac (Hydroxycarbamide)

Hydroxycarbamide inhibits the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides to deoxyribonucleotides. This reduction limits DNA synthesis, leading to decreased proliferation of rapidly dividing cells such as malignant leukocytes and abnormal erythrocytes, and promotes fetal hemoglobin production in sickle cell disease.

The dosage of Hydroxyurea Medac is individualized and must be determined by a qualified prescriber based on the patient’s specific condition, laboratory values, and response to therapy. Dosing is typically started at a low level and adjusted according to clinical monitoring.

Safety data for hydroxycarbamide in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is usually not recommended because the drug can be excreted in milk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Hydroxyurea is the only disease‑modifying oral therapy approved for sickle cell disease, whereas alternatives such as blood transfusions or newer gene‑editing approaches address symptoms or aim for curative intent. Hydroxyurea’s advantage lies in its oral administration and ability to increase fetal hemoglobin, though it requires regular monitoring.

Hydroxyurea Medac tablets should be stored at ambient temperature below 25 °C, kept in the original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer, and keep out of reach of children.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but consistency with regard to meals can help reduce gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and any required fasting.

The most critical risks include severe bone‑marrow suppression leading to aplastic anemia, life‑threatening infections due to neutropenia, renal or hepatic failure, and rare occurrences of secondary malignancies. Prompt reporting of fever, unusual bruising, or signs of organ dysfunction is essential.

Hydroxyurea is contraindicated in individuals with known hypersensitivity to hydroxycarbamide, in patients with severe bone‑marrow failure, and in those receiving concurrent therapies that cause profound myelosuppression unless closely supervised. Pregnant women, unless benefits outweigh risks, should also avoid it.